Maria Sofia Fernandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4799532/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A machine learning approach for single cell interphase cell cycle staging. Scientific Reports, 2021, 11, 19278.	1.6	5
2	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	1.7	37
3	The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression. Cells, 2020, 9, 394.	1.8	60
4	Clinical spectrum and pleiotropic nature of <i>CDH1</i> germline mutations. Journal of Medical Genetics, 2019, 56, 199-208.	1.5	74
5	S100P is a molecular determinant of E-cadherin function in gastric cancer. Cell Communication and Signaling, 2019, 17, 155.	2.7	16
6	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 35-53.	0.8	16
7	Geometric compensation applied to image analysis of cell populations with morphological variability: a new role for a classical concept. Scientific Reports, 2018, 8, 10266.	1.6	6
8	Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer. International Journal of Molecular Sciences, 2017, 18, 2687.	1.8	47
9	Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for <i>KRAS</i> mutant colorectal cancers. Oncotarget, 2016, 7, 68546-68558.	0.8	8
10	Colorectal cancer-related mutant <i>KRAS</i> alleles function as positive regulators of autophagy. Oncotarget, 2015, 6, 30787-30802.	0.8	39
11	Causes and consequences of microsatellite instability in gastric carcinogenesis. World Journal of Gastroenterology, 2014, 20, 16433.	1.4	67
12	Colorectal cancer and RASSF family—A special emphasis on RASSF1A. International Journal of Cancer, 2013, 132, 251-258.	2.3	54
13	Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 1187-1201.	1.5	21
14	Eâ€cadherin dysfunction in gastric cancer ―Cellular consequences, clinical applications and open questions. FEBS Letters, 2012, 586, 2981-2989.	1.3	74
15	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	3.3	137
16	Honey, we need to talk about the membrane progestin receptors. Steroids, 2008, 73, 942-952.	0.8	50
17	Non-genomic progesterone actions in female reproduction. Human Reproduction Update, 2008, 15, 119-138.	5.2	172
18	Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Molecular Human Reproduction, 2006, 12, 435-442.	1.3	79

#	Article	IF	CITATIONS
19	Human Homologs of the Putative G Protein-Coupled Membrane Progestin Receptors (mPRα, β, and γ) Localize to the Endoplasmic Reticulum and Are Not Activated by Progesterone. Molecular Endocrinology, 2006, 20, 3146-3164.	3.7	102
20	Caracterización citogenética molecular de las células germinales masculinas en la azoospermia secretora: parada de la maduración. Revista Internacional De AndrologÃa, 2005, 3, 54-62.	0.1	0
21	Regulated expression of putative membrane progestin receptor homologues in human endometrium and gestational tissues. Journal of Endocrinology, 2005, 187, 89-101.	1.2	120